SPY393.89-3.03 -0.76%
DIA319.39+0.55 0.17%
IXIC11,264.45-270.83 -2.35%

RBC Capital Remains On Sidelines For This MedTech Stock

Stryker Corporation (NYSE: SYK) reported 1Q FY22 results that beat on the top and bottom line, reflecting a solid rebound in procedure volumes in March. 

Benzinga · 04/29/2022 15:11
  • Stryker Corporation (NYSE:SYK) reported 1Q FY22 results that beat on the top and bottom line, reflecting a solid rebound in procedure volumes in March. 
  • SYK expects FY22 organic revenue growth in its 6-8% range. SYK called out the supply chain and inflation issues and expected EPS to come near the low-end of its $9.60-10.00 range. 
  • RBC Capital Market remains on the sidelines at this time and maintains a Sector Perform rating.
  • SYK reported Q1 sales of $4.3 billion, +8.1% Y/Y (+9.2% organic), exceeding consensus estimates and RBC estimate of $4.2 billion. 
  • The beat was broad-based, with numbers coming in above expectations for all sub-segments except for other ortho and neurovascular.
  • While the company did report a bounce back in surgical procedures and declining COVID-19 cases, supply chain challenges and electronic component shortages constrained sales growth. 
  • The impact was felt the most in SYK’s MedSurg business and Medical sub-segment.
  • SYK is also seeing inflation in freight costs hitting margins. SYK expects that Q2 should look similar to Q1 in terms of supply challenges. 
  • While the company does not expect a full recovery in the global supply chain before 2023, it does expect to be able to procure enough to meet demand by year-end.
  • Price Action: SYK shares are down 3.45% at $243.39 during the market session on the last check Friday.